KOD 8-K SEC Filing Analysis

Latest settled — T+20d

KOD ▼ -24.29% at T+20d

NEUTRAL call ✗ call lost -24.29% · α vs SPY -24.31% · entry $41.01 → $31.05

Next anchor: T+60d in 8w

Last close $29.61 (close Jun 8) · -27.80% from $41.01 entry

Entry anchored
May 7, 03:59 PM ET
via Databento tick

T+1d

-2.83%

call -2.83% · α -3.06%

$39.85

settled 5w ago

T+5d

-5.63%

call -5.63% · α -7.10%

$38.70

settled 27d ago

T+20d

-24.29%

call -24.29% · α -24.31%

$31.05

settled 5d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in line with consensus of $0.93. The pre-revenue biotech highlighted positive GLOW2 data and expects DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 readouts. Cash of $169.5M is expected to fund operations into 2027.

Actionable Insight

Traders should focus on upcoming catalysts: DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 data. Cash runway into 2027 provides a buffer. No guidance change; stock likely to trade on pipeline news rather than financials.

Key Facts

Net loss $58.2M, or $0.94 per share, vs $57.5M ($1.09) in Q1 2025
Cash and cash equivalents $169.5M, down from $209.9M at Dec 31, 2025
R&D expenses $48.5M vs $43.6M YoY, driven by increased clinical activities
Zenkuda BLA submission planned; DAYBREAK topline data expected Sep 2026
KSI-101 Phase 3 PEAK topline expected Q4 2026, PINNACLE Q2 2027
No revenue; company is pre-commercial

Financial Impact

Net loss per share $0.94 vs consensus $0.93, essentially in line. Cash burn ~$40M in the quarter.

net losscash positionR&D spend

Risk Factors

Potential delays or failures in Phase 3 trials (DAYBREAK, PEAK, PINNACLE)
Cash burn rate may require additional financing before readouts
BLA submission and approval risks for Zenkuda

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

82% bullish (11 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-211811
Document: kod-20260507.htm	0001193125-26-211811
Document: 0001193125-26-211811-index-headers.html	0001193125-26-211811
Document: 0001193125-26-211811-index.html	0001193125-26-211811
Document: 0001193125-26-211811.txt	0001193125-26-211811
8-K Data (Synthetic)	0001193125-26-211811

2 reports for KOD

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for KOD — sortable, filterable
	Type				Now
May 7, 2026 4w ago	8-K NEUTRAL ★ 4/10	$41.01 $31.05	▼ −24.29%	▼ −24.31%	$29.61 (−27.80%)
Mar 31, 2026 10w ago	8-K BULLISH ★ 8/10	$42.81 $43.67	▲ +2.01%	▼ −7.71%	$29.61 (−30.83%)

US Market Status

Market Closed — Opens in 7h

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access